Carna Biosciences (TSE:4572) Other Stockholders Equity: 円78.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4572 Carna Biosciences Inc TSE:4572
33 GF Score
Price 円332.00
GF Value 円187.46
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Carna Biosciences Other Stockholders Equity?

Carna Biosciences TSE:4572 -2.06% 33 Other Stockholders Equity is 円78.6 Mil as of Dec. 2025. GuruFocus rates TSE:4572 with a GF Score™ of 33/100 and a GF Value™ of 円187.46 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Carna Biosciences's Other Stockholders Equity for the quarter that ended in Dec. 2025 was 円78.6 Mil.

Carna Biosciences's quarterly Other Stockholders Equity increased from Jun. 2025 (円52.7 Mil) to Sep. 2025 (円61.9 Mil) and increased from Sep. 2025 (円61.9 Mil) to Dec. 2025 (円78.6 Mil).

Carna Biosciences's annual Other Stockholders Equity increased from Dec. 2023 (円49.0 Mil) to Dec. 2024 (円82.9 Mil) but then declined from Dec. 2024 (円82.9 Mil) to Dec. 2025 (円78.6 Mil).

Carna Biosciences Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences Other Stockholders Equity Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.63 48.85 48.99 82.92 78.56

Carna Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.61 52.75 61.95 78.56 99.02
TSE:4572
33GF Score
Carna Biosciences Inc TSE:4572
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carna Biosciences Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of 円78.6 Mil mean?
Carna Biosciences (TSE:4572) has a Other Stockholders Equity of 円78.6 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Carna Biosciences and its competitors.
Is Carna Biosciences' Other Stockholders Equity too high?
Carna Biosciences' current Other Stockholders Equity is 円78.6 Mil. Overall, Carna Biosciences has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Other Stockholders Equity compare to VRTX and REGN?
Carna Biosciences' Other Stockholders Equity of 円78.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Carna Biosciences and its competitors. Carna Biosciences's current Other Stockholders Equity is 円78.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円187.46, compared to a current price of 円332.00 — trading 77.1% above its estimated fair value. The current Other Stockholders Equity is 円78.6 Mil. Carna Biosciences' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Other Stockholders Equity is 円78.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円332.00 is trading 77.1% above its estimated GF Value™ of 円187.46. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • Other Stockholders Equity: 円78.6 Mil
  • GF Value™: 円187.46 vs. price of 円332.00 (77.1% above fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
33GF Score

Get the complete analysis for TSE:4572

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円332.00
Price
円187.46
GF Value